http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112920167-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-498 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 |
| filingDate | 2020-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112920167-B |
| titleOfInvention | Dual-target inhibitor targeting FGFR and HDAC, preparation method and application thereof, pharmaceutical composition and medicament |
| abstract | The invention discloses a dual-target inhibitor targeting FGFR and HDAC, a preparation method and application thereof, a pharmaceutical composition and a medicament, and belongs to the field of chemical medicine. The purpose of the present invention is to provide a dual-target inhibitor targeting FGFR and HDAC, a preparation method and application thereof, a pharmaceutical composition and a medicament. Its technical scheme is to provide the compound shown in formula I or II, its pharmaceutically acceptable salt or prodrug, its solvate, its hydrate, its polymorph, its tautomer, its stereoisomer Monomeric or isotopically substituted compounds. The compounds of the present invention can significantly inhibit the activities of FGFR and HDAC proteins, and can also significantly inhibit the proliferation of various tumor cells at the cellular level, providing a new option for the development and application of anti-tumor drugs. |
| priorityDate | 2020-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 251.